This Research Topic is developed in collaboration with 4oncommunity (www.4oncommunity.com Twitter: @4oncommunity), which the Topic Editors are part of, which is a virtual space to share experiences and knowledge for the advancement of the oncology professionals community.
We are experiencing an amazing era of advances in the diagnosis and treatment of breast cancer with the discovery of novel biomarkers and the re-discovery of traditional biomarkers. These biomarkers are strongly impacting pathology and treatment decision-making in oncology, with the introduction of more and more personalized therapeutic options. In this evolving scenario, predictive molecular pathology is called to face new challenges in breast cancer. Our improved diagnostic resolution, together with the combination of clinicopathologic data and massive molecular data, is allowing molecularly targeted therapies to become more selective. Novel biomarkers have been found at the genomic, transcriptomic, proteomic, and immunologic levels, and more precise testing methods and guidelines are predicted.
This Research Topic is designed to provide a comprehensive portrait of our current understanding of molecular biomarkers in breast cancer. One of the aims of this initiative is to foster a novel approach in collaborating between scientists working on breast cancer. We especially welcome Review articles (either systematic or discursive), Original Research studies, and other article types focusing on the role of molecular biomarkers in breast cancer.
• The analysis of traditional biomarkers (i.e. estrogen, ER, and progesterone receptors, PgR, HER2, and proliferation index) in view of novel therapeutic approaches
• Immunotherapy and immuno-oncology of breast cancer
• New molecularly targeted drugs
• Therapeutic protocols and new challenges for the pathologist and molecular biologist.
• Precise – and reproducible – qualitative-quantitative characterization of predictive biomarkers
• Emerging biomarkers, including those based on morphology (e.g. TILs), immunohistochemistry (eg PD-L1), and genomic tests (eg PIK3CA, BRCA, NTRK).
For bioinformatic studies aimed at identifying a candidate set of diagnostic or prognostic markers for diseases, the section Molecular Diagnostics and Therapeutics of Frontiers in Molecular Biosciences will consider for review only those submissions presenting in silico data supported by validating results (independent cohort or in vitro or in vivo validation).
This Research Topic is developed in collaboration with 4oncommunity (www.4oncommunity.com Twitter: @4oncommunity), which the Topic Editors are part of, which is a virtual space to share experiences and knowledge for the advancement of the oncology professionals community.
We are experiencing an amazing era of advances in the diagnosis and treatment of breast cancer with the discovery of novel biomarkers and the re-discovery of traditional biomarkers. These biomarkers are strongly impacting pathology and treatment decision-making in oncology, with the introduction of more and more personalized therapeutic options. In this evolving scenario, predictive molecular pathology is called to face new challenges in breast cancer. Our improved diagnostic resolution, together with the combination of clinicopathologic data and massive molecular data, is allowing molecularly targeted therapies to become more selective. Novel biomarkers have been found at the genomic, transcriptomic, proteomic, and immunologic levels, and more precise testing methods and guidelines are predicted.
This Research Topic is designed to provide a comprehensive portrait of our current understanding of molecular biomarkers in breast cancer. One of the aims of this initiative is to foster a novel approach in collaborating between scientists working on breast cancer. We especially welcome Review articles (either systematic or discursive), Original Research studies, and other article types focusing on the role of molecular biomarkers in breast cancer.
• The analysis of traditional biomarkers (i.e. estrogen, ER, and progesterone receptors, PgR, HER2, and proliferation index) in view of novel therapeutic approaches
• Immunotherapy and immuno-oncology of breast cancer
• New molecularly targeted drugs
• Therapeutic protocols and new challenges for the pathologist and molecular biologist.
• Precise – and reproducible – qualitative-quantitative characterization of predictive biomarkers
• Emerging biomarkers, including those based on morphology (e.g. TILs), immunohistochemistry (eg PD-L1), and genomic tests (eg PIK3CA, BRCA, NTRK).
For bioinformatic studies aimed at identifying a candidate set of diagnostic or prognostic markers for diseases, the section Molecular Diagnostics and Therapeutics of Frontiers in Molecular Biosciences will consider for review only those submissions presenting in silico data supported by validating results (independent cohort or in vitro or in vivo validation).
